BIOMAT Database Logo BIOMAT Database Logo

Oral valgancyclovir versus intravenous gancyclovir for cytomegalovirus prophylaxis in kidney transplant recipients. 2007

T Said, and M R N Nampoory, and A S Pacsa, and S Essa, and N Madi, and N Fahim, and M Abraham, and P Nair, and T Al-Otaibi, and M A Halim, and K V Johny, and M Al-Mousawi
Hamed Al-Essa Organ Transplant Centre, Ibn Sina Hospital, Kuwait. tsaid2000@hotmail.com

BACKGROUND Prophylaxis against cytomegalovirus (CMV) is a regular practice in organ transplantation. Oral valgancyclovir appears to be an interesting alternative to the usual intravenous form. METHODS We prospectively compared the response of intravenous gancyclovir for 2 weeks (GAN; n=41) to oral valgancyclovir for 2 weeks (VAL2w; n=23) or 3 months (VAL3m; n=46) in kidney transplant recipients receiving induction immunosuppression. CMV antigenemia assay and/or polymerase chain reaction (PCR) were used for viral detection. Patients were followed for a minimum of 6 months posttransplantation. SPSS software was used for statistical analysis using a cutoff of significance as P<.05. RESULTS There was no statistical difference in the demographic features among the study groups. However, human leukocyte antigen (HLA) match was better in the VAL3m group and the patients of this group received less ATG induction immunosuppression (41.3%) compared with the GAN group (100%). The incidence of acute rejection was not different among the study groups. There was a higher incidence of fever with positive CMV tests in the VAL2w group (P=.035) compared with the other groups, while leukopenia with a negative CMV test was significantly higher in the VAL3m group (P=.04). The incidence of CMV disease was higher in the VAL2w group (30.4%) compared with the GAN group (14.6%) or the VAL3m group (8.7%). Renal function was significantly worse in the VAL2w group at 3 and 6 months (P=.011 and .02, respectively). CONCLUSIONS Three months oral valgancyclovir prophylaxis for CMV was a more effective regimen compared with intravenous gancyclovir for 2 weeks. Shorter courses were associated with a higher incidence of CMV infection and poorer graft function. Leukopenia observed in patients receiving valgancyclovir may be a drug-related side effect.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011183 Postoperative Complications Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery. Complication, Postoperative,Complications, Postoperative,Postoperative Complication
D003586 Cytomegalovirus Infections Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults. CMV Inclusion,CMV Inclusions,Congenital CMV Infection,Congenital Cytomegalovirus Infection,Cytomegalic Inclusion Disease,Cytomegalovirus Colitis,Cytomegalovirus Inclusion,Cytomegalovirus Inclusion Disease,Cytomegalovirus Inclusions,Inclusion Disease,Perinatal CMV Infection,Perinatal Cytomegalovirus Infection,Renal Tubular Cytomegalovirus Inclusion,Renal Tubular Cytomegalovirus Inclusions,Salivary Gland Virus Disease,Severe Cytomegalovirus Infection,Severe Cytomegalovirus Infections,Infections, Cytomegalovirus,CMV Infection, Congenital,CMV Infection, Perinatal,Colitis, Cytomegalovirus,Congenital CMV Infections,Congenital Cytomegalovirus Infections,Cytomegalic Inclusion Diseases,Cytomegalovirus Colitides,Cytomegalovirus Inclusion Diseases,Cytomegalovirus Infection,Cytomegalovirus Infection, Congenital,Cytomegalovirus Infection, Perinatal,Cytomegalovirus Infection, Severe,Cytomegalovirus Infections, Severe,Disease, Cytomegalic Inclusion,Disease, Cytomegalovirus Inclusion,Diseases, Cytomegalovirus Inclusion,Inclusion Disease, Cytomegalic,Inclusion Disease, Cytomegalovirus,Inclusion Diseases,Inclusion Diseases, Cytomegalovirus,Inclusion, CMV,Inclusion, Cytomegalovirus,Infection, Congenital CMV,Infection, Congenital Cytomegalovirus,Infection, Cytomegalovirus,Infection, Perinatal CMV,Infection, Perinatal Cytomegalovirus,Infection, Severe Cytomegalovirus,Perinatal CMV Infections,Perinatal Cytomegalovirus Infections
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077562 Valganciclovir A ganciclovir prodrug and antiviral agent that is used to treat CYTOMEGALOVIRUS RETINITIS in patients with AIDS, and for the prevention of CYTOMEGALOVIRUS INFECTIONS in organ transplant recipients who have received an organ from a CMV-positive donor. Ganciclovir L-valyl Ester,Valcyt,Valcyte,Valganciclovir Hydrochloride,Ganciclovir L valyl Ester
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations

Related Publications

T Said, and M R N Nampoory, and A S Pacsa, and S Essa, and N Madi, and N Fahim, and M Abraham, and P Nair, and T Al-Otaibi, and M A Halim, and K V Johny, and M Al-Mousawi
Preemptive therapy versus valgancyclovir prophylaxis in cytomegalovirus-positive kidney transplant recipients receiving antithymocyte globulin induction.
November 2012, Transplantation proceedings,
T Said, and M R N Nampoory, and A S Pacsa, and S Essa, and N Madi, and N Fahim, and M Abraham, and P Nair, and T Al-Otaibi, and M A Halim, and K V Johny, and M Al-Mousawi
Pre-emptive intravenous ganciclovir versus valganciclovir prophylaxis for de novo cytomegalovirus-seropositive kidney-transplant recipients.
October 2010, Transplant international : official journal of the European Society for Organ Transplantation,
T Said, and M R N Nampoory, and A S Pacsa, and S Essa, and N Madi, and N Fahim, and M Abraham, and P Nair, and T Al-Otaibi, and M A Halim, and K V Johny, and M Al-Mousawi
Cytomegalovirus prophylaxis in kidney transplant recipients.
December 1995, ANNA journal,
T Said, and M R N Nampoory, and A S Pacsa, and S Essa, and N Madi, and N Fahim, and M Abraham, and P Nair, and T Al-Otaibi, and M A Halim, and K V Johny, and M Al-Mousawi
Oral ganciclovir versus valganciclovir for cytomegalovirus prophylaxis in high-risk liver transplant recipients.
April 2009, Transplant infectious disease : an official journal of the Transplantation Society,
T Said, and M R N Nampoory, and A S Pacsa, and S Essa, and N Madi, and N Fahim, and M Abraham, and P Nair, and T Al-Otaibi, and M A Halim, and K V Johny, and M Al-Mousawi
Prophylaxis for cytomegalovirus in pancreas transplant recipients using intravenous ganciclovir.
December 1995, Transplantation proceedings,
T Said, and M R N Nampoory, and A S Pacsa, and S Essa, and N Madi, and N Fahim, and M Abraham, and P Nair, and T Al-Otaibi, and M A Halim, and K V Johny, and M Al-Mousawi
A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients.
December 1998, Transplantation,
T Said, and M R N Nampoory, and A S Pacsa, and S Essa, and N Madi, and N Fahim, and M Abraham, and P Nair, and T Al-Otaibi, and M A Halim, and K V Johny, and M Al-Mousawi
Acyclovir prophylaxis of cytomegalovirus disease in kidney transplant recipients.
September 1999, Transplantation proceedings,
T Said, and M R N Nampoory, and A S Pacsa, and S Essa, and N Madi, and N Fahim, and M Abraham, and P Nair, and T Al-Otaibi, and M A Halim, and K V Johny, and M Al-Mousawi
Studies evaluating high-dose acyclovir, intravenous immune globulin, and cytomegalovirus hyperimmunoglobulin for prophylaxis against cytomegalovirus in kidney transplant recipients.
December 1996, The Annals of pharmacotherapy,
T Said, and M R N Nampoory, and A S Pacsa, and S Essa, and N Madi, and N Fahim, and M Abraham, and P Nair, and T Al-Otaibi, and M A Halim, and K V Johny, and M Al-Mousawi
[Prophylaxis of cytomegalovirus infections with ganciclovir in kidney transplant recipients].
December 1992, Presse medicale (Paris, France : 1983),
T Said, and M R N Nampoory, and A S Pacsa, and S Essa, and N Madi, and N Fahim, and M Abraham, and P Nair, and T Al-Otaibi, and M A Halim, and K V Johny, and M Al-Mousawi
Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients.
January 2003, Transplantation,
Copied contents to your clipboard!